Glucagon-like peptide-1 receptor agonists demonstrate growing acceptance as therapeutic agents for both glycemic regulation and weight control in patients with type 2 diabetes and obesity. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.